Hostname: page-component-7b7567c8c-kwt9d Total loading time: 0 Render date: 2026-11-15T00:28:43.988Z Has data issue: false hasContentIssue false

Addendum1: Pharmacology and psychiatry

Published online by Cambridge University Press:  09 July 2009

Extract

Interest has recently focused on the possibility that the efficacy of drugs used in schizophrenia depends on their ability to alter disposition of cerebral dopamine. Thus, Phenothiazines and butyrophenones elevate dopamine turnover in the brain. (Andén, Roos, and Werdinius, 1964; Laverty and sharman, 1965; Sharman, 1966; Andén, Butcher, Corrodi, Fuxe, and Ungerstedt, 1970); Compounds which are clinically the most potent are those with greatest effect on dopamine turnover (Laverty and Sharman, 1965; O'Keeffe, Sharman, and Vogt, 1970). Augmented turnover is thought to be a consequence of the blockade of central dopamine receptors by these drugs. X-ray crystallography has revealed a similarity of the dopamine conformation to part of the chlorpromazine structure, suggesting that of the chlorpromazine structure, suggesting that phenothiazines can occupy dopamine receptors (Horn and snyder, 1971). More conclusively, in cats, dogs, and rabbits, chlorpromazine antagonized vascular effects of dopamine (Rossum, 1966; Yeh, McNay, and Goldberg, 1969; Brotzu, 1970); and haloperidol considerably diminished motor effects evoked by dopamine infused into the brain of cats and fowls (Cools and Rossum, 1970; Marley and Nistico, 1972).

Information

Type
Addendum
Copyright
Copyright © Cambridge University Press 1972

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable